Fluidigm Licenses CFTR Next-Generation Sequencing Assay From Baylor Genetics for Use With the Juno System
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) and Baylor Genetics today announced that they have entered into a licensing agreement to offer a next-generation sequencing (NGS) library prep assay that enables efficient sequencing of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Under the agreement, Fluidigm obtains the rights to commercialize the CFTR library prep... Read more